DHT-UN DRI Healthcare Trust
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About DRI Healthcare Trust (TSE: DHT-UN)
›
DRI Healthcare Trust (TSE: DHT-UN) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 32 employees.
The shares were at 18.95 CAD on 19 November 2026, up 22.5% over 52 weeks. Its 52-week range is 15.00 CAD to 19.84 CAD: the price is 4.5% below the high and 26.3% above the low.
At a market capitalisation of 1.07B CAD, it trades at 12.6 times trailing earnings and 4.8 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 49% for DHT-UN. It pays a dividend yielding 3.29% (it pays out 40% of its earnings), against a median of 1.90% among the dividend payers in that peer group.
DRI Healthcare Trust reports return on equity of -11.5%, an operating margin of 33.7% and revenue down 3.8% year over year.
Its debt exceeds its cash by 566.16M USD, a debt-to-equity ratio of 0.86. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 25.06 CAD is 32.3% above the current price. The next earnings report is expected on 3 March 2027.